At 12 months, eleven patients were switched to imatinib maintenance, of them 3 (27%) patients were switched back to nilotinib 300 mg twice daily after 18, 24, 51 months respectively: one patient because of loss of CCyR (BCR-ABL: 0.11% IS) on imatinib after 18 months, and two patients because of imatinib intolerance (grade 3 myalgias). The gene discussed is ABL1; the disease is Myalgia.